KZIA

Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kazia Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

Kazia Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

Kazia Therapeutics Ltd (KZIA) has 9 emplpoyees as of December 15 2025.

Today KZIA has the market capitalization of 111.94M USD.